- Home
- CRDF vs NUW Comparison
CRDF vs NUW Comparison
Compare CRDF & NUW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- NUW
- Stock Information
- Founded
- CRDF 1999
- NUW 2008
- Country
- CRDF United States
- NUW United States
- Employees
- CRDF N/A
- NUW N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- NUW Investment Managers
- Sector
- CRDF Health Care
- NUW Finance
- Exchange
- CRDF Nasdaq
- NUW Nasdaq
- Market Cap
- CRDF 233.5M
- NUW 245.0M
- IPO Year
- CRDF N/A
- NUW N/A
- Fundamental
- Price
- CRDF $4.04
- NUW $13.69
- Analyst Decision
- CRDF Strong Buy
- NUW
- Analyst Count
- CRDF 6
- NUW 0
- Target Price
- CRDF $11.92
- NUW N/A
- AVG Volume (30 Days)
- CRDF 1.4M
- NUW 45.3K
- Earning Date
- CRDF 08-07-2025
- NUW 01-01-0001
- Dividend Yield
- CRDF N/A
- NUW 3.66%
- EPS Growth
- CRDF N/A
- NUW N/A
- EPS
- CRDF N/A
- NUW N/A
- Revenue
- CRDF $587,000.00
- NUW N/A
- Revenue This Year
- CRDF N/A
- NUW N/A
- Revenue Next Year
- CRDF N/A
- NUW N/A
- P/E Ratio
- CRDF N/A
- NUW N/A
- Revenue Growth
- CRDF N/A
- NUW N/A
- 52 Week Low
- CRDF $2.01
- NUW $12.45
- 52 Week High
- CRDF $5.64
- NUW $14.44
- Technical
- Relative Strength Index (RSI)
- CRDF 65.93
- NUW 50.63
- Support Level
- CRDF $3.07
- NUW $13.64
- Resistance Level
- CRDF $4.22
- NUW $13.85
- Average True Range (ATR)
- CRDF 0.22
- NUW 0.11
- MACD
- CRDF 0.08
- NUW 0.00
- Stochastic Oscillator
- CRDF 87.35
- NUW 42.23
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.